MedTrace Logo

To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets

NCT00946608 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability study of Loratadine 10 mg tablets.

Conditions

  • Allergy

Interventions

DRUG

Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)

DRUG

Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)

DRUG

Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)

Sponsors & Collaborators

Principal Investigators

  • Gaetano Morelli, M.D. · Early Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2005-08-31
Completion
2005-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00946608 on ClinicalTrials.gov